Bruker (NASDAQ:BRKR) Cut to Peer Perform at Wolfe Research

Wolfe Research cut shares of Bruker (NASDAQ:BRKR) from an outperform rating to a peer perform rating in a report issued on Monday morning, MarketBeat reports.

A number of other brokerages also recently commented on BRKR. The Goldman Sachs Group lowered their price objective on Bruker from $72.00 to $60.00 and set a sell rating for the company in a research report on Tuesday, July 9th. Citigroup lowered their price objective on Bruker from $95.00 to $80.00 and set a buy rating for the company in a research report on Wednesday, July 10th. Jefferies Financial Group started coverage on Bruker in a research report on Monday, June 3rd. They set a buy rating and a $85.00 price objective for the company. TD Cowen lowered their price objective on Bruker from $74.00 to $72.00 and set a hold rating for the company in a research report on Wednesday, August 7th. Finally, Wells Fargo & Company assumed coverage on Bruker in a research note on Tuesday, August 27th. They set an overweight rating and a $78.00 target price for the company. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Bruker has an average rating of Hold and an average target price of $81.40.

Bruker Stock Up 1.0 %

Shares of NASDAQ:BRKR opened at $67.46 on Monday. The business has a 50-day moving average price of $65.29 and a 200 day moving average price of $71.48. The company has a current ratio of 1.65, a quick ratio of 0.75 and a debt-to-equity ratio of 1.18. The company has a market capitalization of $9.80 billion, a price-to-earnings ratio of 24.53, a PEG ratio of 2.43 and a beta of 1.18. Bruker has a 12-month low of $53.79 and a 12-month high of $94.86.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Tuesday, August 6th. The medical research company reported $0.52 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.52. The firm had revenue of $800.70 million during the quarter, compared to the consensus estimate of $799.44 million. Bruker had a return on equity of 24.92% and a net margin of 11.29%. The company’s quarterly revenue was up 17.4% on a year-over-year basis. During the same period last year, the company earned $0.50 EPS. Sell-side analysts expect that Bruker will post 2.61 EPS for the current year.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 16th. Investors of record on Monday, September 2nd were issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.30%. The ex-dividend date of this dividend was Friday, August 30th. Bruker’s dividend payout ratio is presently 7.27%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BRKR. TD Asset Management Inc grew its holdings in Bruker by 7.4% in the first quarter. TD Asset Management Inc now owns 1,788,763 shares of the medical research company’s stock valued at $168,036,000 after purchasing an additional 123,984 shares during the last quarter. Congress Asset Management Co. MA grew its holdings in Bruker by 3.5% in the first quarter. Congress Asset Management Co. MA now owns 1,414,362 shares of the medical research company’s stock valued at $132,865,000 after purchasing an additional 47,301 shares during the last quarter. Marshall Wace LLP grew its holdings in Bruker by 127.8% in the second quarter. Marshall Wace LLP now owns 1,389,537 shares of the medical research company’s stock valued at $88,666,000 after purchasing an additional 779,549 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Bruker by 8.6% in the second quarter. Dimensional Fund Advisors LP now owns 1,277,273 shares of the medical research company’s stock valued at $81,508,000 after purchasing an additional 101,539 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in Bruker by 3.0% in the second quarter. Bank of New York Mellon Corp now owns 966,069 shares of the medical research company’s stock valued at $61,645,000 after purchasing an additional 27,870 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.